Is This News a Setback or a Step Forward for CRISPR Therapeutics?
A big week for CRISPR Therapeutics (NASDAQ: CRSP) has gotten even bigger as the biotech company is awaiting a crucial decision. The U.S. Food and Drug Administration (FDA) expects to decide on Friday whether to approve what may become CRISPR Therapeutics' very first product -- exa-cel, a gene-editing treatment for blood disorders.
And now, in unrelated news, CRISPR Therapeutics has cut two of its more advanced immuno-oncology candidates to favor second-generation alternatives -- and expand into autoimmune diseases. One of the cancer candidates, CTX-110, was involved in a phase 2 potentially registrational trial, meaning the study could have supported a regulatory request. So, is this latest move a setback for the biotech company or a step forward?
Image source: Getty Images.
Source Fool.com
